Dry Eye Syndrome: Clinical Trials

20 trials for Dry Eye Syndrome, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

16 completed, 3 unknown, 1 withdrawn. 20 Phase 3, 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 320Completed 16, Unknown 3, Withdrawn 1
Phase 25Completed 5

Follow Dry Eye Syndrome: new trials by email Literature Review of Dry Eye Syndrome trials Research Report on Dry Eye Syndrome

Trials (filtered) newest first · largest first

All 20 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Assess Symptom Relief and Product Tolerability of ABBV-444 Drops in Adult Participants
ABBV-444 - Dry Eye Syndrome
Phase 3CompletedAbbVie402023-06-272024-10-15
Comprehensive Study on Dry Eye and Ocular Surface Disease Prior and After Cataract Surgery
The study will include three arms, one non interventional and 2 interventions. The intervention arms will include two commercially available sodium hyaluronate 0.1% (Systane ultra plus and Hylo-comod) - Dry Eye Disease, Dry Eye Syndrome
Phase 3UnknownFundación Oftalmológica Los Andes1002021-01-152021-01-15
Evaluating the Efficacy and Safety of TJO-087 in Moderate to Severe Dry Eye Disease Patients
TJO-087, Cyclosporine ophthalmic solution 0.05% - Dry Eye Syndrome
Phase 3UnknownTaejoon Pharmaceutical Co., Ltd.1822020-06-192022-02-18
Safety and Efficacy of BRM421 for Dry Eye Syndrome Treatment
BRM421, Placebo - Dry Eye Syndrome
Phase 2 / Phase 3CompletedBRIM Biotechnology Inc.2202020-01-152026-05-01
Vehicle-Controlled Study of SkQ1 as Treatment for Dry-eye Syndrome
SkQ1 Vehicle Solution, SkQ1 Ophthalmic Solution - Dry Eye Syndrome
Phase 3CompletedMitotech, SA6102019-12-202022-01-19
Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome
0.05% Voclosporin Ophthalmic Solution (VOS), 0.10% VOS, 0.20% VOS - Dry Eye Syndrome, Keratoconjunctivitis Sicca
Phase 2 / Phase 3CompletedAurinia Pharmaceuticals Inc.5082019-10-142021-12-10
Study of TOP1630 for Dry Eye Syndrome
TOP1630 0.1% Ophthalmic Solution TID OU, Placebo to TOP1630 0.1% Ophthalmic Solution TID OU - Dry Eye Syndrome
Phase 2 / Phase 3CompletedTopivert Pharma Ltd2022019-02-132019-08-07
Study of SkQ1 as Treatment for Dry-eye Syndrome
Low Dose - SkQ1, High dose - SkQ1, SkQ1 (Vehicle) - Dry Eye Syndrome
Phase 3CompletedMitotech, SA4522018-12-062022-01-19
Efficacy and Safety of HU007 Eye Drops in Patients With Dry Eye Syndrome
HU007, Restasis, Moisview - Dry Eye Syndrome
Phase 3CompletedHuons Co., Ltd.2092018-01-222020-05-08
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2
RGN-259, Placebo - Dry Eye Syndrome
Phase 3CompletedReGenTree, LLC6012016-11-012026-10-21
Study to Evaluate the Efficacy and Safety of CKD-350
Xenobella, Isotonic 0.3% Sodium Hyaluronate - Dry Eye Syndrome
Phase 3UnknownChong Kun Dang Pharmaceutical1382016-05-012016-05-19
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1
RGN-259, Placebo - Dry Eye Syndrome
Phase 2 / Phase 3CompletedReGenTree, LLC3172015-09-012019-10-17
Assessment of Tear Film Thickness by Optical Coherence Tomography in Healthy Subjects and Subjects With Dry Eye Disease
GENTEAL HA® Eye Drops (NOVARTIS, Switzerland), Physiological Sodium Chloride solution (0,9%) - Dry Eye Syndrome
Phase 3WithdrawnMedical University of Vienna2014-12-012014-11-14
Efficacy and Safety of T2762 and Vismed® in Dry Eye Syndrome
T2762, Vismed® - Dry Eye Syndrome
Phase 3CompletedLaboratoires Thea1052013-12-012017-08-24
The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy
Methylprednisolone, Esomeprazole - Thyroid-associated Ophthalmopathy, Dry Eye Syndrome
Phase 3CompletedMedical University of Vienna182013-06-272020-02-20
Efficacy and Safety of HE10 for Dry Eye Syndrome
HE 10, Restasis - Dry Eye Syndrome
Phase 3CompletedHuons Co., Ltd.1012013-05-012015-07-08
Efficacy and Safety of Rebamipide in Subjects With Dry Eye Syndrome
Rebamipide 2% ophthalmic suspension, Placebo (vehicle) - Dry Eye Syndrome
Phase 3CompletedKubota Vision Inc.5642012-06-012014-05-07
Sodium Hyaluronate Ophthalmic Solution, 0.18% for Treatment of Dry Eye Syndrome
Sodium Hyaluronate Ophthalmic Solution, 0.18%, Vehicle - Dry Eye Syndrome
Phase 3CompletedAlcon Research19362011-07-012013-07-08
Evaluation of the Effect of Repeated Usage on the Tear Film Characteristics of an Investigational Eye Drop in Dry Eye Sufferers
Carboxymethylcellulose sodium, glycerin and polysorbate 80 - Dry Eye Syndrome
Phase 2 / Phase 3CompletedOptometric Technology Group Ltd402011-03-012013-11-28
A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease
Bromfenac Ophthalmic Solution A, Bromfenac Ophthalmic Solution B, Placebo Comparator - Dry Eye Syndrome
Phase 3CompletedBausch & Lomb Incorporated8402010-09-012020-09-04

Narrower conditions

Dry Eye Syndromes (20)  ·  Keratoconjunctivitis (2)  ·  Cataract (1)  ·  Graves Ophthalmopathy (1)  ·  Keratoconjunctivitis Sicca (1)

Broader conditions

Eye Diseases (20)  ·  Lacrimal Apparatus Diseases (20)  ·  Conjunctival Diseases (3)  ·  Conjunctivitis (3)  ·  Corneal Diseases (3)  ·  Keratitis (3)  ·  Autoimmune Diseases (1)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)  ·  Endocrine System Diseases (1)  ·  Exophthalmos (1)  ·  Eye Diseases, Hereditary (1)  ·  Genetic Diseases, Inborn (1)  ·  Goiter (1)  ·  Graves Disease (1)  ·  Hyperthyroidism (1)

Interventions

Cyclosporins (2)  ·  Visomitin (2)  ·  thymosin beta(4) (2)  ·  Cyclosporine (1)  ·  Esomeprazole (1)  ·  Hyaluronic Acid (1)  ·  Methylprednisolone (1)  ·  rebamipide (1)

Sponsors

Huons Co., Ltd. (2)  ·  Medical University of Vienna (2)  ·  Mitotech, SA (2)  ·  ReGenTree, LLC (2)  ·  AbbVie (1)  ·  Alcon Research (1)  ·  Aurinia Pharmaceuticals Inc. (1)  ·  BRIM Biotechnology Inc. (1)  ·  Bausch & Lomb Incorporated (1)  ·  Chong Kun Dang Pharmaceutical (1)  ·  Fundación Oftalmológica Los Andes (1)  ·  Kubota Vision Inc. (1)  ·  Laboratoires Thea (1)  ·  Optometric Technology Group Ltd (1)  ·  Taejoon Pharmaceutical Co., Ltd. (1)

Countries

United States (10)  ·  South Korea (3)  ·  Austria (2)  ·  France (1)  ·  United Kingdom (1)

Top investigators

Gail Torkildsen, MD (3)  ·  Lawrence T Friedhoff, MD, PhD (2)  ·  Blair Boehmer, MD (1)  ·  Choun-Ki Joo (1)  ·  Cristobal Loezar Hernandez, MD (1)  ·  David Wirta, MD (1)  ·  Eugene B McLaurin, MD (1)  ·  Felipe Valenzuela Santana, MD (1)  ·  Gerhard Garhoefer, MD (1)  ·  Hyo Myung Kim, MD, PhD (1)  ·  HyoMyung Kim, MD (1)  ·  Juan Stoppel Ortiz, MD (1)  ·  Luis Montecinos Buneder, MD (1)

Results publications

PMID 36450107